Clinical TrialID 8191

Oral Dronabinol-HIV

NCT06034314

HIV

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final clinical_trial record.

Clinical Trial Id
8191
Evidence Id
8191
Core Evidence Id
8191
Source Clinical Trial Id
8189
Herb2 Clinical Trial Id
HBCT008189
Nct Id
NCT06034314
Title
Oral Dronabinol-HIV
Status
Recruiting
Phase
Phase 1
Study Result
No
Study Condition
HIV
Study Type
Interventional
Study Design
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER
Intervention
DRUG: Dronabinol Capsules
Intervention Allocation
Non_Randomized
Intervention Model
Parallel
Intervention Mask
Intervention Purpose
Other
Gender
All
Age
Adult, Older_Adult
Enrollment
160
Outcome Measure
Change in Dronabinol-induced transcriptome profile in blood using single cell (sc)RNA-seq, Changes at baseline, 120 minutes, and 360 minutes post oral Dronabinol. Transcriptome will be profiled by using single cell (sc)RNA-seq in blood samples. A panel of 45 cytokines and profiling of 37 immune cell types will be assessed for functional evaluation after Dronabinol administration., Baseline, 120 minutes post-Dronabinol and 360 minutes post-Dronabinol
Sponsor Collaborator
Yale University|National Institute on Drug Abuse (NIDA)
Funded By
OTHER
Location
Connecticut Mental Health Center, New Haven, Connecticut, 06511, United States
Other Id
2000035807|1R01DA052846-01
Start Date
2023-09-21
Primary Completion Date
2025-10-01
Completion Date
2027-10-01
First Posted
2023-09-13
Results First Posted
Last Update Posted
2024-07-11
Study Document
Study Url
https://clinicaltrials.gov/study/NCT06034314
Title Cn
Title En
Oral Dronabinol-HIV
Bilingual Status
semi_complete